பிலிப்பைன் மருத்துவ சங்கம் ப்ரெஸிடெஂட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Published June 6, 2021 9:01pm
Oral antiviral drug molnupiravir entered its third phase of clinical trials as a possible treatment for the coronavirus disease 2019 at the Lung Center of the Philippines.
Developed by Ridgeback Biotherapeutics LP and Merck & Co., the drug could be taken as an oral pill by patients who exhibit COVID-19 symptoms and test positive for the disease.
At present, two patients are undergoing the trial at the Lung Center of the Philippines, which seeks more volunteers moving forward. The volunteers take the drug twice a day for at least five days.
Among those qualified to be included in the trial are symptomatic patients who tested positive within the past five days, aged 18 and above, and have yet to be vaccinated. ....

Jon Viktor Cabuenas , Leo Olarte , Philippine Medical Association , Merck Co , Health Undersecretary Maria Rosario Vergeire , Lung Center , Undersecretary Maria Rosario Vergeire , Philippine Medical Association President , Jon Viktor , Ovid 19 News Philippines , Covid 19 Therapeutics , லியோ ஓளடர்த்ே , பிலிப்பைன் மருத்துவ சங்கம் , மெர்க் இணை , நுரையீரல் மையம் , பிலிப்பைன் மருத்துவ சங்கம் ப்ரெஸிடெஂட் , ஜான் விக்டர் ,